ArticleOrthopaedic journal of sports medicine2020
Bone Marrow Concentrate Injection Treatment Improves Short-term Outcomes in Symptomatic Hip Osteoarthritis Patients: A Pilot Study.
Article in Orthopaedic journal of sports medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05465096 (Interventional Pilot Study on the Treatment of Osteoarthritis of the Hip Joint With Intra-articular Ultrasound-guided Infiltration of Microfractured Autologous Adipose Tissue Containing Mesenchymal Stromal Cells), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Interventional Pilot Study on the Treatment of Osteoarthritis of the Hip Joint With Intra-articular Ultrasound-guided Infiltration of Microfractured Autologous Adipose Tissue Containing Mesenchymal Stromal Cells
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Management of hip osteoarthritis: harnessing the potential of mesenchymal stem cells-a systematic review.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2024Pooled it
- Systematic evidence analysis of symptom modification in hip osteoarthritis following MSC-based interventions.Wiener klinische Wochenschrift · 2026Review
- Platelet-Rich Plasma Versus Bone Marrow Aspirate Concentrate for Hip Disorders: A Narrative Review of Biological Rationale, Clinical Evidence, and Research Priorities.Bioengineering (Basel, Switzerland) · 2026Review
- Review
- Article
- Intra-articular administration of autologous adipose-derived stem cells in hip osteoarthritis: Longitudinal treatment trajectories and prognostic factors.Regenerative therapy · 2025Article
- Orthobiologic injections for hip osteoarthritis: A systematic review of clinical outcomes.Orthopedic reviews · 2025Article
- Safety and Efficacy of Bone-Marrow Aspirate Concentrate in Hip Osteoarthritis: A Systematic Review of Current Clinical Evidence.Indian journal of orthopaedics · 2024Review
- Bone marrow aspirate injection for osteoarthritis of the hip; A pilot study.Interventional pain medicine · 2022Article
- Orthobiologic Injections for the Treatment of Hip Osteoarthritis: A Systematic Review.Journal of clinical medicine · 2022Review
- Arthroscopy Association of Canada Position Statement on Intra-articular Injections for Hip Osteoarthritis.Orthopaedic journal of sports medicine · 2022Article
- Biological Augments for Acetabular Chondral Defects in Hip Arthroscopy-A Scoping Review of the Current Clinical Evidence.Current reviews in musculoskeletal medicine · 2021Article
- What the papers say.Journal of hip preservation surgery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteoarthritis (OA) is one of the leading causes of disability in the United States, the hip being the second most affected weightbearing joint. Autologous bone marrow concentrate (BMC) is a promising alternative therapy to conventional treatments, with the potential to mitigate inflammation and improve joint function. PURPOSE: To investigate the effectiveness of a single intra-articular BMC injection for patients with symptomatic hip OA. STUDY
designCase series; Level of evidence, 4.
methodsA total of 24 patients diagnosed with symptomatic hip OA who elected to undergo a single BMC injection were prospectively enrolled in the study. Patients were excluded if they reported a preinjection Numeric Rating Scale (NRS) score for pain with activity of <6 points out of 10. The Western Ontario and McMaster Universities Arthritis Index (WOMAC), modified Harris Hip Score (mHHS), Hip Outcome Score-Activities of Daily Living (HOS-ADL), 12-Item Short Form Health Survey (SF-12), and NRS pain scores were collected before and after the procedure (6 weeks, 3 months, and 6 months). Joint space and Tönnis OA grade scores were recorded on preinjection anteroposterior pelvis radiographs.
resultsA total of 18 hips from 16 patients (7 male and 9 female) (mean age, 57.6 ± 11; mean body mass index, 25.9 ± 3.6 kg/m
conclusionA single BMC injection can significantly improve subjective pain and function scores up to 6 months in patients with symptomatic hip OA. Further studies are warranted to evaluate BMC treatment against other therapeutics in a larger sample size and compare the biological signature profiles that may be responsible for the therapeutic effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.